Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11beta-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids
Understanding how these preferences evolve could help guide formulation strategies across categories such as functional beverages, protein products and nutritional foods, where nutrient density and satiety are increasingly valued
Advantages Non-invasive compared to subcutaneous injection
doi:10.1016/j.pcad.2024.12.010
Y., Yigit A., Dogruoz R
Currently available GLP-1 receptor agonists in the United States include exenatide (Byetta, Bydureon BCise), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and tirzepatide (Mounjaro, Zepbound), though tirzepatide is technically a dual GIP/GLP-1 receptor agonist